ADDENDUM NO. SIX TO EMPLOYMENT AGREEMENT
This Addendum Number SIX (this “Addendum”) to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020, April 15, 2021, March 15, 2022 and December 28, 2022 and October 17, 2023 (the “Employment Agreement”) that was entered into by and between IMMUNIC, INC., a Delaware corporation (the “Company”), and DUANE NASH (the “Executive”), is entered into as of August 29, 2024. Defined terms used, but not defined, herein shall have the meaning set forth in the Employment Agreement.
WHEREAS, the Executive agreed to serve in the capacity of Executive Chairman of the Board of Directors of the Company (“Board”), pursuant to the terms of the Employment Agreement, until December 31, 2024 or such later date as shall be mutually agreed to in writing by the Executive and the Company; and
WHEREAS, the Executive and the Company have agreed to extend the term of the Executive’s service as the Executive Chairman of the Board until December 31, 2025 subject to the terms of the Employment Agreement.
NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, and for other valuable consideration, the Company and the Executive hereby agree as follows:
1. Term of Employment. The Company and the Executive hereby agree to extend the Term of Employment from December 31, 2024 to December 31, 2025 with a Base Salary of $33,987 per month (which includes the cash retainer payable for serving on the Company’s Board or for acting as the Chairman of the Board). All other terms of the Employment Agreement shall remain the same and Section 12 (Miscellaneous) of the Employment Agreement is deemed incorporated herein to this Addendum.
IN WITNESS WHEREOF, the parties hereto have caused this Addendum to be executed as of August 29, 2024.
| IMMUNIC, INC. | ||
| By: | /s/ Daniel Vitt | |
| Name: | Daniel Vitt | |
| Title: | Chief Executive Officer | |
| EXECUTIVE | ||
| /s/ Duane Nash | ||
| Duane Nash | ||